T-Cell Depletion by Immune Rosettes and T-cell–specific Magnetic Microbeads (CD2 + CD7) Obtained From Normal Donors and T-ALL Patients
| Antibody Used . | Normal Donors (n = 9) . | T-ALL (n = 7) . | ||||
|---|---|---|---|---|---|---|
| Apheresis (−) . | Immune Rosettes (CD11b + CD6) . | D-column (CD2 + CD7) . | Apheresis (−) . | Immune Rosettes (CD11b + CD6) . | D-column (CD2 + CD7) . | |
| Total cells (×109) | 43.7 (17.2-66) | 5.7 (1-13.8) | 3.5 (0.1-10.8) | 33.9 (18.2-53.4) | 4.4 (1.7-8) | 2.5 (0.9-6) |
| % overall cell loss | 88 (76-96) | 93 (83-99) | 86 (77-96) | 92 (83-97) | ||
| CD34+cells (×109) | 0.3 (0.07-1) | 0.2 (0.08-0.7) | 0.2 (0.06-0.5) | 0.4 (0.2-0.8) | 0.3 (0.2-0.6) | 0.3 (0.1-0.6) |
| %CD34+ cells | 0.7 (0.2-1.8) | 5.3 (2.7-7.9) | 14 (3-37) | 1.3 (0.4-2.8) | 9 (4-21) | 14 (4-25) |
| %CD34 recovery | 87 (59-100) | 76 (53-100) | 92 (69-100) | 73 (57-100) | ||
| %CD34 enrichment fold | 12 (3-41) | 28 (3-74) | 9 (4-21) | 14 (5-28) | ||
| CD11b+cells (×109) | 29.3 (11.4-50.2) | 3 (0.1-11.6) | 1.9 (0.02-10.2) | 25.9 (9.1-50.6) | 2.7 (6.3-9.7) | 1.2 (0.02-3) |
| %CD11b+ cells | 67 (54-79) | 38 (7-84) | 38 (2-95) | 71 (50-95) | 59 (18-83) | 39 (0.2-78) |
| %CD11b+cell loss | 91 (72-99) | 95 (80-100) | 89 (73-96) | 94 (87-100) | ||
| CD3+cells (×109) | 11.6 (3.8-20.9) | 1.4 (0.3-4.1) | 0.02 (0.0002-0.1) | 6 (0.6-14.3) | 1 (0.1-2.8) | 0.008 (0.0007-0.03) |
| %CD3+ cells | 26 (9-49) | 36 (6-81) | 0.3 (0.1-1) | 23 (1-49) | 23 (3-63) | 0.2 (0.1-0.5) |
| %CD3+ cell loss | 84 (57-98) | 99.7 (99.4-100) | 82 (68-96) | 99.9 (99.2-100) | ||
| CD19+ cells (×109) | 1.8 (0.6-2.8) | 0.6 (0.08-1) | 0.3 (0.02-0.7) | 0.1 (0.06-0.2) | 0.03 (0.003-0.07) | 0.01 (0.0006-0.05) |
| %CD19+cells | 4 (2-7) | 16 (3-50) | 29 (0.2-69) | 0.4 (0.1-1.4) | 0.5 (0.1-1.5) | 0.3 (0.1-0.8) |
| %CD19+ cell loss | 71 (61-87) | 82 (66-98) | 74 (38-98) | 84 (20-99) | ||
| Antibody Used . | Normal Donors (n = 9) . | T-ALL (n = 7) . | ||||
|---|---|---|---|---|---|---|
| Apheresis (−) . | Immune Rosettes (CD11b + CD6) . | D-column (CD2 + CD7) . | Apheresis (−) . | Immune Rosettes (CD11b + CD6) . | D-column (CD2 + CD7) . | |
| Total cells (×109) | 43.7 (17.2-66) | 5.7 (1-13.8) | 3.5 (0.1-10.8) | 33.9 (18.2-53.4) | 4.4 (1.7-8) | 2.5 (0.9-6) |
| % overall cell loss | 88 (76-96) | 93 (83-99) | 86 (77-96) | 92 (83-97) | ||
| CD34+cells (×109) | 0.3 (0.07-1) | 0.2 (0.08-0.7) | 0.2 (0.06-0.5) | 0.4 (0.2-0.8) | 0.3 (0.2-0.6) | 0.3 (0.1-0.6) |
| %CD34+ cells | 0.7 (0.2-1.8) | 5.3 (2.7-7.9) | 14 (3-37) | 1.3 (0.4-2.8) | 9 (4-21) | 14 (4-25) |
| %CD34 recovery | 87 (59-100) | 76 (53-100) | 92 (69-100) | 73 (57-100) | ||
| %CD34 enrichment fold | 12 (3-41) | 28 (3-74) | 9 (4-21) | 14 (5-28) | ||
| CD11b+cells (×109) | 29.3 (11.4-50.2) | 3 (0.1-11.6) | 1.9 (0.02-10.2) | 25.9 (9.1-50.6) | 2.7 (6.3-9.7) | 1.2 (0.02-3) |
| %CD11b+ cells | 67 (54-79) | 38 (7-84) | 38 (2-95) | 71 (50-95) | 59 (18-83) | 39 (0.2-78) |
| %CD11b+cell loss | 91 (72-99) | 95 (80-100) | 89 (73-96) | 94 (87-100) | ||
| CD3+cells (×109) | 11.6 (3.8-20.9) | 1.4 (0.3-4.1) | 0.02 (0.0002-0.1) | 6 (0.6-14.3) | 1 (0.1-2.8) | 0.008 (0.0007-0.03) |
| %CD3+ cells | 26 (9-49) | 36 (6-81) | 0.3 (0.1-1) | 23 (1-49) | 23 (3-63) | 0.2 (0.1-0.5) |
| %CD3+ cell loss | 84 (57-98) | 99.7 (99.4-100) | 82 (68-96) | 99.9 (99.2-100) | ||
| CD19+ cells (×109) | 1.8 (0.6-2.8) | 0.6 (0.08-1) | 0.3 (0.02-0.7) | 0.1 (0.06-0.2) | 0.03 (0.003-0.07) | 0.01 (0.0006-0.05) |
| %CD19+cells | 4 (2-7) | 16 (3-50) | 29 (0.2-69) | 0.4 (0.1-1.4) | 0.5 (0.1-1.5) | 0.3 (0.1-0.8) |
| %CD19+ cell loss | 71 (61-87) | 82 (66-98) | 74 (38-98) | 84 (20-99) | ||